Related Experiment Video
Updated: Apr 28, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Quantitative Evaluation of Model-Informed Drug Development Implementation in China's Approved Innovative Drugs: From
Jian Li1,2, Zhenlei Wang3, Chunmin Wei1,2
1Center of Drug Evaluation, National Medical Products Administration, Beijing, China.
Abstract:
Model-informed drug development (MIDD) has emerged as a cornerstone paradigm in global pharmaceutical innovation. Historically underutilized in China, MIDD methodologies gained momentum following the National Medical Products Administration's (NMPA) 2020 release of the Model-Informed Drug Development Technical Guideline, which was subsequently augmented by supplementary technical guidelines to systematically promote and institutionalize MIDD adoption. This study conducts a longitudinal analysis of MIDD implementation in China-approved innovative drugs from 2018 to 2024, spanning pre- and post-guideline eras.
More Related Videos
08:47Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
Published on: September 28, 2022
05:59An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
Published on: November 4, 2022
Related Concept Videos
Drug Discovery: Overview
Clinical Trials: Overview
Drug Regulation
Biopharmaceutical Factors Influencing Drug Product Design: Overview
FDA Approved Drugs: Changes to Approved Drugs
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions